Терапия синдрома фибромиалгии на современном этапе
https://doi.org/10.14412/1996-7012-2014-2-76-82
Аннотация
В статье приводятся данные о патогенетически значимых параметрах, участвующих в восприятии боли при фибромиалгии (ФМ): повышенная чувствительность или плотность допаминовых D2-рецепторов, усиление болевого сигнала в связи с увеличением уровня субстанции Р и недостаточная его модификация, обусловленная низким уровнем серотонина, феномен аллодинии, психосоматический компонент.
Приведены новые классификационные критерии ФМ и оценка тяжести симптомов, входящих в эти критерии. Показано, как изменилась терапия боли при ФМ за последнее десятилетие: уменьшение использования периферических анальгетических средств, трициклических антидепрессантов, возрастание частоты назначения ингибиторов обратного захвата серотинина (дулоксетина, милнаципрана) и прегабалина. Продемонстрированы эффективность и удовлетворительная переносимость прегабалина при боли. Проведено сравнение эффективности и переносимости дулоксетина, милнаципрана и прегабалина по данным 17 рандомизированных контролируемых исследований.
Об авторах
Н.В. Чичасова
ФГБУ «Научно-исследовательский институт ревматологии им В.А. Насоновой» РАМН, Москва, Россия
Россия
Россия
Е.В. Иголкина
ФГБУ «Научно-исследовательский институт ревматологии им В.А. Насоновой» РАМН, Москва, Россия
Россия
Россия
Литература
1. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general; population. Arthritis Rheum. 1995;38(1):19–28. DOI: http://dx.doi.org/10.1002/art.1780380104. 2. Moork PJ, Nilsen TI. Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway. Arthritis Rheum. 2012;64(1):281–4. DOI: 10.1002/art.33346.
2. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1):19–28. DOI: http://dx.doi.org/10.1002/art.1780380104.
3. Чичасова НВ. Синдром фибромиалгии: клиника, диагностика, лечение. Русский медицинский журнал. 1999;6(18):1190–4.
4. [Chichasova NV. Fibromialgiya syndrome: clinic, diagnostics, treatment. Russkii med- itsinskii zhurnal. 1999;6(18):1190–4. (In Russ.)]
5. Gran JT. The epidemiology of chronic generalized musculoskeletal pain. Best Pract Res Clin Rheumatol. 2003;17(4):547–61. DOI: http://dx.doi.org/10.1016/S1521-6942(03)00042-1.
6. Sauer K, Kemper C, Glaeske G, et al. Fibromyalgia syndrome: Prevalence pharmacological and non-pharmacological interventions in outpatient health care. An analysis of statutory health insurance data. Joint Bone Spine. 2011;78(1):80–4. DOI: 10.1016/j.jbspin.2010.05.003. Epub 2010 Jul 31.
7. White KP, Speechley M, Harth M, Ostbye T. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario: the London Fibromyalgia Epidemiology Study. Arthritis Rheum. 1999;42(1):76–83. DOI: http://dx.doi.org/10.1002/1529-0131(199901)42:1%3C76::AID-ANR10%3E3.0.CO;2-G.
8. Reyero F, Ponte G, Rodriguez-Jimenez R, et al. High frequency of childhood ADHD history in women with fibromyalgia. Eur Psychiatry. 2011;26(8):483–4. DOI: 10.1016/j.eurpsy.2010.03.012. Epub 2010 Jul 10. 9. Burda CD, Cox FR, Osborne P. Histocompatibility antigens in the fibrositis (fibromyalgia) syndrome. Clin Exp Rheumatol. 1986;4(4):355–8.
9. 10. Yunus MB, Khan MA, Rawlings KK, et al. Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol. 1999;26(2):409–12.
10. Biasi G, Fioravanti A, Galeazzi M, et al. Absence of correlation between HLA antigens and fibromyalgia syndrome in Italian patients. Ann Ital Med Int. 1994;9(4):228–30.
11. Russell IJ, Vaeroy H, Javos M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35(5):550–6. DOI: http://dx.doi.org/10.1002/art.1780350509.
12. Offenbaecher M, Bondy B, Jonge S, et al. Possible association of a fibromyalgia with a polymorphism in the transporter gene regulatory region. Arthritis Rheum. 1999;42(11):2482–8. DOI: http://dx.doi.org/10.1002/1529-0131(199911)42:11%3C2482::AID-ANR27%3E3.0.CO;2-B.
13. Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLRP) polymorphism, and relationship to anxiety-related personality trials. Arthritis Rheum. 2002;46(3):845–7. http://dx.doi.org/10.1002/art.10103.
14. Bondly B, Spaeth M, Offenbaecher M, et al. The T102C polymorphism of the 5-HT2A-recetor gene in fibromyalgia. Neurobiol Dis. 1999;6(5):433–9. DOI: http://dx.doi.org/10.1006/nbdi.1999.0262. 16. Frank B, Niesler B, Bondly B, et al. Mutational analysis of serotonin receptor genes HTR3A and HTR3B in fibromyalgia patients. Clin Rhematol. 2004;23(4):338–44. DOI: http://dx.doi.org/10.1007/s10067-004- 0927-2. Epub 2004 May 7.
15. Wood PB, Patterson 2nd JC, Sunderland JJ, et al. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with position emissio tomography: a pilot study. J Pain. 2007;8(1):51–8. DOI: http://dx.doi.org/10.1016/j.jpain.2006.05.014. Epub 2006 Oct 4.
16. Malt EA, Olafsson S, Aakvag A, et al. Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with budpirone in women with fibromyalgia compared to female population based con- trols. J Affect Disord. 2003;75(1):77–82. DOI: http://dx.doi.org/10.1016/S0165- 0327(02)00025-3.
17. Buskila D, Cohen H, Neumann L, Ebstein RP. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relation- ship to novely seeking personality traits. Mol Psychiatry. 2004;9(8):730–1. DOI: http://dx.doi.org/10.1038/sj.mp.4001506.
18. Russel IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of sub- stance p in patients with the fibromyalgia syn- drome. Arthritis Rheum. 1994;37(11):1593–601. DOI: http://dx.doi.org/10.1002/art.1780371106. 21. Terman GW, Bonica JJ. Spinal mechanisms and their modulation. In: Bonica’s management of pain. Loeser JD, Butler SH, Chapman CR, editors. Philadelphia. PA: Lippincott-Williams & Wilkins; 2001. Р. 73–152.
19. Ablin JN, Bar-Shira A, Yaron M, et al. Possible association between fibromyalgia and a novel 1354 G>C polymorphism in the TACRI (substance P receptor) gene in Ashkenazi patients. Arthritis Rheum. 2005;(Suppl):S269.
20. Cagnie B, Coppieters I, Denecker S, et al. Central sensitization in fibromyalgia? A systematic review on structural and functional brain VRI. Semin Arthritis Rheum. 2004 Jan 8. pii: S0049-0172(14)00002-X. DOI: 10.1016/j.semarthrit.2014.01.001.
21. Ablin J, Neumann L, Buskila D. Pathogenesis of fibromyalgia – a review. Joint Bone Spine. 2008;75(3):273–9. DOI: 10.1016/j.jbspin.2007.09.010. Epub 2008 Mar 28.
22. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmental pain processing in fibromyalgia. Arthritis Rheum. 2002;46(5):1333–43. DOI: http://dx.doi.org/10.1002/art.10225.
23. Yunus MB. Fibromyalgia syndrome: clinical features and spectrum. In: The fibromyalgia syndrome: current research and future directions in epidemiology, pathogenesis, and treatment. Pillemer SR, editor. New York: Haworth Medical; 1994. P. 5–21.
24. Чичасова НВ, Насонов ЕЛ, Иголкина ЕВ, Фоломеев МЮ. Применение трамадола гидрохлорид (Трамала) в ревматологической практике. Клиническая фармакология и терапия. 1999;8(1):69–72. [Chichasova NV, Nasonov EL, Igolkina EV, Folomeev MYu. Application of tramadol a hydrochloride (Tramala) in rheumatologic practice. Klinicheskaya farmakologiya i terapiya. 1999;8(1):69–72. (In Russ.)]
25. Wolfe F, Smythe HA, Yunas MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160–72. DOI: http://dx.doi.org/10.1002/art.1780330203.
26. Wolfe F, Clauw DJ, Fitzcharles M-A, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62(5):600–10. DOI: 10.1002/acr.20140. 30. Mease P, Arnold LM, Choy EH, et al.; OMERACT Fibromyalgia Working Group. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009;36(10):2318–29. DOI: 10.3899/jrheum.090367.
27. Choy EH, Arnold LM, Clauw DJ, et al. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2009;36(10):2330–4. DOI: 10.3899/jrheum.090368.
28. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl. 2005;75:6–21.
29. Mease P, Arnold LM, Bennett R, et al. Fibromyalgia syndrome. J Rheumatol. 2007;34(6):1415–25.
30. Bigatti SM, Hernandez AM, Cronan TA, Rand KL. Sleep disturbance in fibromyalgia syndrome: relationship to pain and depres- sion. Arthritis Rheum. 2008;59(7):961–7. DOI: 10.1002/art.23828.
31. Rossy LA, Buckelew SP, Dorr N, et al. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med. 1999;21(2):180–91. DOI: http://dx.doi.org/10.1007/BF02908299.
32. Wolfe F, Wallit BT, Katz RS, et al. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. Eur J Pain. 2013;17(4):585–6. DOI: 10.1002/j.1532-2149.2012.00234.x. Epub 2012 Nov 21.
33. Affaitati G, Constantini R, Fabrizio A, et al. Effects of treatment of peripheral pain generators in fibromyalgia patients. Eur J Pain. 2011;15(1):61–9. DOI: 10.1016/j.ejpain.2010.09.002.
34. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome. Arthritis Rheum. 2005;52(4):1264–73. DOI: http://dx.doi.org/10.1002/art.20983.
35. Mease PJ, Russel IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheum. 2008;35(3):502–14. Epub 2008 Feb 15.
36. Arnold LM, Russel IJ, Dirl EW, et al. A 14-week, randomized, double-blind, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9(9):792–805. DOI: 10.1016/j.jpain.2008.03.013. Epub 2008 Jun 3.
37. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6 month double-blind, placebo-controlled trial with pregabalin. J Pain. 2008;136(3):419–31. DOI: 10.1016/j.pain.2008.02.027. Epub 2008 Apr 8.
38. Arnold LM, Claw DJ, Dunegan J, et al. A framework for fibromyalgia management for primary care providers. Mayo Clin Proc. 2012;87(5):488–96. DOI: 10.1016/j.may-ocp.2012.02.010.
39. Hansor W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetin, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010;11(6):505–21. DOI: 10.1016/j.jpain.2010.01.002. Epub 2010 Apr 24.
40. Cathey MA, Wolfe F, Kleimheksel SM, et al. Functional ability and work status in patient with fibromyalgia. Arthritis Rheum. 1998;41:85–98.
41. Cormsen L, Rosenberg R, Bach F, et al. Depression, anxiety, health-related quality of life and pain in patients with chronic fibromyalgia and neuropathic pain. Eur J Pain. 2010;14(2):127.e1-8. DOI: 10.1016/j.ejpain.2009.03.010. Epub 2009 May 26.
Рецензия
Для цитирования:
Чичасова Н., Иголкина Е. Терапия синдрома фибромиалгии на современном этапе. Современная ревматология. 2014;8(2):76-82. https://doi.org/10.14412/1996-7012-2014-2-76-82
For citation:
Chichasova N., Igolkina E. Current therapy of fibromyalgia syndrome. Modern Rheumatology Journal. 2014;8(2):76-82. (In Russ.) https://doi.org/10.14412/1996-7012-2014-2-76-82
Просмотров: 1385
Послать статью по эл. почте 